Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study
View ORCID ProfileChristian Holm Hansen, Astrid Blicher Schelde, Ida Rask Moustsen-Helm, Hanne-Dorthe Emborg, Tyra Grove Krause, Kåre Mølbak, Palle Valentiner-Branth on behalf of the Infectious Disease Preparedness Group at Statens Serum Institut
doi: https://doi.org/10.1101/2021.12.20.21267966
Christian Holm Hansen
1Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark
Astrid Blicher Schelde
1Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark
Ida Rask Moustsen-Helm
1Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark
Hanne-Dorthe Emborg
1Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark
Tyra Grove Krause
2Epidemiological Infectious Diseases Preparedness Statens Serum Institut, Copenhagen, Denmark
Kåre Mølbak
2Epidemiological Infectious Diseases Preparedness Statens Serum Institut, Copenhagen, Denmark
Palle Valentiner-Branth
1Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark

Data Availability
De-identified data are available for access to members of the scientific and medical community for non-commercial use only upon reasonable request to the authors
Posted December 22, 2021.
Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study
Christian Holm Hansen, Astrid Blicher Schelde, Ida Rask Moustsen-Helm, Hanne-Dorthe Emborg, Tyra Grove Krause, Kåre Mølbak, Palle Valentiner-Branth
medRxiv 2021.12.20.21267966; doi: https://doi.org/10.1101/2021.12.20.21267966
Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study
Christian Holm Hansen, Astrid Blicher Schelde, Ida Rask Moustsen-Helm, Hanne-Dorthe Emborg, Tyra Grove Krause, Kåre Mølbak, Palle Valentiner-Branth
medRxiv 2021.12.20.21267966; doi: https://doi.org/10.1101/2021.12.20.21267966
Subject Area
Subject Areas
- Addiction Medicine (227)
- Allergy and Immunology (501)
- Anesthesia (110)
- Cardiovascular Medicine (1233)
- Dermatology (147)
- Emergency Medicine (282)
- Epidemiology (10012)
- Gastroenterology (498)
- Genetic and Genomic Medicine (2448)
- Geriatric Medicine (236)
- Health Economics (479)
- Health Informatics (1636)
- Health Policy (751)
- Hematology (248)
- HIV/AIDS (532)
- Medical Education (252)
- Medical Ethics (74)
- Nephrology (268)
- Neurology (2277)
- Nursing (139)
- Nutrition (350)
- Oncology (1245)
- Ophthalmology (375)
- Orthopedics (133)
- Otolaryngology (226)
- Pain Medicine (155)
- Palliative Medicine (50)
- Pathology (324)
- Pediatrics (729)
- Primary Care Research (282)
- Public and Global Health (4828)
- Radiology and Imaging (834)
- Respiratory Medicine (650)
- Rheumatology (283)
- Sports Medicine (226)
- Surgery (266)
- Toxicology (44)
- Transplantation (125)
- Urology (99)